CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia

SEATTLE, Sept. 29, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration ( " FDA " or " the Agency " ), the Company has...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials